Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma

Philipp Lohneis; Marianne Sinn; Fritz Klein; Sven Bischoff; Jana K Striefler; Lilianna Wislocka; Bruno V Sinn; Uwe Pelzer; Helmut Oettle; Hanno Riess; Carsten Denkert; Hendrik Bläker; Anja Jühling

doi:10.1038/s41416-018-0093-y

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma

Standard

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. / Lohneis, Philipp; Sinn, Marianne; Klein, Fritz; Bischoff, Sven; Striefler, Jana K; Wislocka, Lilianna; Sinn, Bruno V; Pelzer, Uwe; Oettle, Helmut; Riess, Hanno; Denkert, Carsten; Bläker, Hendrik; Jühling, Anja.

in: BRIT J CANCER, Jahrgang 118, Nr. 11, 05.2018, S. 1485-1491.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lohneis, P, Sinn, M, Klein, F, Bischoff, S, Striefler, JK, Wislocka, L, Sinn, BV, Pelzer, U, Oettle, H, Riess, H, Denkert, C, Bläker, H & Jühling, A 2018, 'Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma', BRIT J CANCER, Jg. 118, Nr. 11, S. 1485-1491. https://doi.org/10.1038/s41416-018-0093-y

APA

Lohneis, P., Sinn, M., Klein, F., Bischoff, S., Striefler, J. K., Wislocka, L., Sinn, B. V., Pelzer, U., Oettle, H., Riess, H., Denkert, C., Bläker, H., & Jühling, A. (2018). Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. BRIT J CANCER, 118(11), 1485-1491. https://doi.org/10.1038/s41416-018-0093-y

Vancouver

Lohneis P, Sinn M, Klein F, Bischoff S, Striefler JK, Wislocka L et al. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. BRIT J CANCER. 2018 Mai;118(11):1485-1491. https://doi.org/10.1038/s41416-018-0093-y

Bibtex

@article{7e07642e159a4e7db862d5c60054f442,

title = "Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma",

abstract = "BACKGROUND: The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial.METHODS: Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0.238 mm2).RESULTS: Tumour budding was significantly associated with a higher tumour grade (p < 0.001) but not with distant or lymph node metastasis. Regardless of the quantification approach, an increased number of tumour buds was significantly associated with reduced disease-free survival (DFS) and overall survival (OS) (10 HPF approach DFS: HR = 1.056 (95% CI 1.022-1.092), p = 0.001; OS: HR = 1.052 (95% CI 1.018-1.087), p = 0.002; consensus method DFS: HR = 1.037 (95% CI 1.017-1.058), p < 0.001; OS: HR = 1.040 (95% CI 1.019-1.061), p < 0.001). Recently published cut-offs for tumour budding in colorectal cancer were prognostic in PDAC as well.CONCLUSIONS: Tumour budding is prognostic in the CONKO-001 clinical cohort of patients. Further standardisation and validation in additional clinical cohorts are necessary.",

keywords = "Aged, Aged, 80 and over, Carcinoma, Pancreatic Ductal/pathology, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Grading, Pancreatic Neoplasms/pathology, Prognosis, Prospective Studies, Retrospective Studies, Tumor Burden",

author = "Philipp Lohneis and Marianne Sinn and Fritz Klein and Sven Bischoff and Striefler, {Jana K} and Lilianna Wislocka and Sinn, {Bruno V} and Uwe Pelzer and Helmut Oettle and Hanno Riess and Carsten Denkert and Hendrik Bl{\"a}ker and Anja J{\"u}hling",

year = "2018",

month = may,

doi = "10.1038/s41416-018-0093-y",

language = "English",

volume = "118",

pages = "1485--1491",

journal = "BRIT J CANCER",

issn = "0007-0920",

publisher = "NATURE PUBLISHING GROUP",

number = "11",

}

RIS

TY - JOUR

T1 - Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma

AU - Lohneis, Philipp

AU - Sinn, Marianne

AU - Klein, Fritz

AU - Bischoff, Sven

AU - Striefler, Jana K

AU - Wislocka, Lilianna

AU - Sinn, Bruno V

AU - Pelzer, Uwe

AU - Oettle, Helmut

AU - Riess, Hanno

AU - Denkert, Carsten

AU - Bläker, Hendrik

AU - Jühling, Anja

PY - 2018/5

Y1 - 2018/5

N2 - BACKGROUND: The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial.METHODS: Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0.238 mm2).RESULTS: Tumour budding was significantly associated with a higher tumour grade (p < 0.001) but not with distant or lymph node metastasis. Regardless of the quantification approach, an increased number of tumour buds was significantly associated with reduced disease-free survival (DFS) and overall survival (OS) (10 HPF approach DFS: HR = 1.056 (95% CI 1.022-1.092), p = 0.001; OS: HR = 1.052 (95% CI 1.018-1.087), p = 0.002; consensus method DFS: HR = 1.037 (95% CI 1.017-1.058), p < 0.001; OS: HR = 1.040 (95% CI 1.019-1.061), p < 0.001). Recently published cut-offs for tumour budding in colorectal cancer were prognostic in PDAC as well.CONCLUSIONS: Tumour budding is prognostic in the CONKO-001 clinical cohort of patients. Further standardisation and validation in additional clinical cohorts are necessary.

AB - BACKGROUND: The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial.METHODS: Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0.238 mm2).RESULTS: Tumour budding was significantly associated with a higher tumour grade (p < 0.001) but not with distant or lymph node metastasis. Regardless of the quantification approach, an increased number of tumour buds was significantly associated with reduced disease-free survival (DFS) and overall survival (OS) (10 HPF approach DFS: HR = 1.056 (95% CI 1.022-1.092), p = 0.001; OS: HR = 1.052 (95% CI 1.018-1.087), p = 0.002; consensus method DFS: HR = 1.037 (95% CI 1.017-1.058), p < 0.001; OS: HR = 1.040 (95% CI 1.019-1.061), p < 0.001). Recently published cut-offs for tumour budding in colorectal cancer were prognostic in PDAC as well.CONCLUSIONS: Tumour budding is prognostic in the CONKO-001 clinical cohort of patients. Further standardisation and validation in additional clinical cohorts are necessary.

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Pancreatic Ductal/pathology

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Pancreatic Neoplasms/pathology

KW - Prognosis

KW - Prospective Studies

KW - Retrospective Studies

KW - Tumor Burden

U2 - 10.1038/s41416-018-0093-y

DO - 10.1038/s41416-018-0093-y

M3 - SCORING: Journal article

C2 - 29755112

VL - 118

SP - 1485

EP - 1491

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 11

ER -